Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Preveceutical Medical Inc C.PREV

Alternate Symbol(s):  PRVCF

PreveCeutical Medical Inc. is a Canada-based health sciences company. The Company’s principal business activity is the development of options for preventive and curative therapies utilizing organic and nature identical products. The Company’s pipeline includes Cannabinoid Sol-Gel, Non-Addictive Analgesic, BSV Peptide Program and Dual Gene Therapy. Its Cannabinoid Sol-Gel is a cannabinoid-based nose-to-brain delivery system that provides relief to a range of indications from pain, inflammation, seizures, and neurological disorders. Its Dual Gene Therapy for curative and prevention therapies for diabetes and obesity. Its Nature Identical peptides for treatment of various ailments. Its BSV peptide program targets cancer progression. Its nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).


CSE:PREV - Post by User

Bullboard Posts
Post by TBone22on Apr 20, 2019 3:46pm
130 Views
Post# 29651315

Bridgemark Scandal

Bridgemark Scandal

Graeme Wood / Glacier Media
April 9, 2019 04:56 PM

BCSC lawyer Graham MacLennan said Tuesday there are now 82 subjects of the investigation, up from what was understood to be 62.

Glacier Media attended the panel’s hearing Tuesday. Recordings were not allowed and affidavits were not released to the public.

But MacLennan told the panel that the investigation has so far resulted in 116 production orders, including 14 to share-issuing companies, 44 to banks, 10 to brokerage firms, 36 to individuals and 12 to other entities. About 300 bank accounts and 230 brokerage accounts connected to subjects have been searchedBrady alleged that between February 2018 and August 2018 that so-called consultants privately bought at least $50.9 million worth of stock at pennies per share but had most of the money returned in alleged phoney consulting fees – a process described by Brady as like a “cash swap.”

When the dust settles on this scandal, those of us who are long on Prev are gonna be very happy.

 

Bullboard Posts